Malakoplakia, a medical, surgical, pathological and radiological enigma, is an infrequent chronic inflammatory condition that can affect many organ systems, including the gastrointestinal tract, integument, skeletal system and genitourinary tract. Review of the literature has shown that malakoplakia presents in paediatric as well as adult populations, and that it is associated with impaired immune function. Variable clinical manifestations as well as the sometimes non-specific radiological findings of malakoplakia can be misleading, making diagnosis quite difficult. We present a clinical case of renal malakoplakia mimicking a malignant renal carcinoma in a 62-year-old woman. This report highlights the importance of awareness of malakoplakia in the differential diagnosis for renal masses and renomegaly. This case can serve as a reminder that things are not always what they seem, and it reinforces the idea that unusual disease entities should be explored to aid in achieving a correct diagnosis and, thus, potentially avoid unnecessary treatment.
Female urinary incontinence is prevalent, costly and morbid. Participants in a NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) sponsored summit reviewed findings from NIH (National Institutes of Health) funded clinical research on urinary incontinence in women and discussed the future of urinary incontinence research. The NIDDK convened the Summit on Urinary Incontinence Clinical Research in Women on March 14, 2014. Participants representing a broad range of clinical expertise reviewed completed NIH sponsored urinary incontinence related studies, including results from community based epidemiological studies such as the BACH (Boston Area Community Health) Survey and from randomized clinical trials such as PRIDE (Program to Reduce Incontinence by Diet and Exercise), and studies conducted by the Pelvic Floor Disorders Network and the Urinary Incontinence Treatment Network. BACH Survey results improved our understanding of precursors, incidence, prevalence and natural history of urinary incontinence in a diverse group of women. The Pelvic Floor Disorders Network study found that anticholinergic medications and onabotulinumtoxinA are efficacious for treating urge urinary incontinence, and Burch colposuspension and retropubic mid urethral polypropylene slings are efficacious for decreasing stress urinary incontinence following pelvic organ prolapse surgery in women with potential stress urinary incontinence. The Urinary Incontinence Treatment Network study found that fascial slings were better than colposuspension, and that retropubic and transobturator mid urethral polypropylene slings were equivalent for stress urinary incontinence. In patients with stress urinary incontinence a preoperative urodynamic study was noninferior to basic office examinations for surgical outcome. The addition of behavioral intervention did not allow female patients to discontinue antimuscarinics for urge urinary incontinence. PRIDE showed that modest weight reductions significantly decreased urinary incontinence. Strategies for future research on urinary incontinence should include a focus on early disease, risk factor identification, better phenotyping, incorporation of new technologies, patient centered research and prevention.
1 October 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Double-J ureteral stents are an invaluable tool in urology and are one of the most widely used stents in the world. However, when left in situ for prolonged periods, so-called “retained” ureteral stents can lead to numerous complications such as migration, hematuria, encrustation, or stent occlusion. These complications present severe challenges in urologic management. Notably, encrustation of ureteral stents may increase the risk of renal impairment and other potentially life-threatening complications. Here, we present the case of a 34-year-old female with a left double-J ureteral stent who presented to the Emergency Department (ED) with a one-day history of left flank pain and febrile urinary tract infection.
Background/Objectives: Secondary pelvic cancer (SC) risk after radiotherapy (RT) for prostate cancer (PC) remains uncertain; we performed an updated synthesis of observational studies and randomized trials. Methods: We reviewed systematic reviews, meta-analyses, and randomized trials published in 2001–2025 evaluating SC risk after RT for PC. Given potential detection bias from RT-related rectal or bladder bleeding, the primary outcome was relative risk (RR) of death. Results: Across 12 reports—eight systematic reviews/meta-analyses and four randomized trials—comparators were predominantly RP or mixed cohorts; review-level sample sizes were not summed because of potential overlap. In randomized data with >10 years of follow-up, SC occurred in 25.3% of RT-treated patients versus 20.8% in RP/hormone therapy groups, while deaths from other cancers occurred in 8.5% versus 7.2%. The median converted RR of death from SC was 1.05. These estimates may be influenced by unmeasured lifestyle factors such as smoking and baseline comorbidities, which were not accounted for in observational cohorts and are more common among patients receiving RT, who are often less likely to be RP candidates. Conclusions: RT is associated with a small but consistent increase in SC, with a 4.5% absolute excess incidence over >10 years. The observed 1.3% absolute difference in deaths from other cancers was modest and similar in magnitude to the reported perioperative mortality range of approximately 0.2–1.1% after RP, although these risks occur over substantially different time horizons. The smaller excess seen in randomized trials than in retrospective studies suggests that much of the apparent risk in prior reports may reflect confounding and/or detection bias rather than direct radiation effect.